Outcome of older patients with acute myeloid leukemia: An Analysis of SEER Data over 3 Decades

Cancer

Volumn 119, Issue 15, 2013, Pages 2720-2727

  Thein, Mya S ^a,b   Ershler, William B ^c   Jemal, Ahmedin ^d   Yates, Jerome W ^c,e   Baer, Maria R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Institute for Advanced Studies on Aging   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; age; Surveillance, Epidemiology and End Results data; survival

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; TREND STUDY;

ACUTE MYELOID LEUKEMIA; AGE; SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS DATA; SURVIVAL;

AGE FACTORS; AGED; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84880570189     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28129     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
2. Estey E, Dohner H,. Acute myeloid leukaemia. Lancet. 2006; 368: 1894-1907.
3. Phekoo KJ, Richards MA, Moller H, Schey SA,. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast England. Haematologica. 2006; 91: 1400-1404.
4. Burnett A, Wetzler M, Lowenberg B,. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011; 29: 487-494.
5. Lichtman MA,. A historical perspective on the development of the cytarabine (7 days) and daunorubicin (3 days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis. 2013; 50: 119-130.
6. Burnett AK,. The treatment of AML: current status and novel approaches. Hematology. 2005; 10 (suppl 1): 50-53.
7. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M,. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood. 2009; 113: 3666-3672.
8. Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol. 2012; 13: 207-214.
9. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood. 1981; 58: 1203-1212.
10. Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60: 454-462.
11. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF,. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973; 57: 485-488.
12. Yates JW,. Comorbidity considerations in geriatric oncology research. CA Cancer J Clin. 2001; 51: 329-336.
13. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 3481-3485.
14. Stirewalt DL, Kopecky KJ, Meshinchi S, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001; 97: 3589-3595.
15. Kurata M, Hasegawa M, Nakagawa Y, et al. Expression dynamics of drug resistance genes, multidrug resistance 1 (MDR1) and lung resistance protein (LRP) during the evolution of overt leukemia in myelodysplastic syndromes. Exp Mol Pathol. 2006; 81: 249-254.
16. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012; 118: 3377-3386.
17. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005; 104: 1998-2005.
18. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29: 3457-3465.
19. Baer MR, Gojo I,. Novel agents for the treatment of acute myeloid leukemia in the older patient. J Natl Compr Canc Netw. 2011; 9: 331-335.
20. Cherubini A, Del Signore S, Ouslander J, Semla T, Michel JP,. Fighting against age discrimination in clinical trials. J Am Geriatr Soc. 2010; 58: 1791-1796.
21. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Research Data, November 2010 Submission (1973-2008) -Linked to County Attributes, Total US, 1969-2009 Counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2011.
22. Brenner H, Gefeller O, Hakulinen T,. Period analysis for "up-to-date" cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004; 40: 326-335.
23. Dickman PW, Adami HO,. Interpreting trends in cancer patient survival. J Intern Med. 2006; 260: 103-117.
24. Henson DE, Ries LA,. The relative survival rate. Cancer. 1995; 76: 1687-1688.
25. Neugarten BL,. The future and the young-old. Gerontologist. 1975; 15: 4-9.
26. Hakulinen T, Seppa K, Lambert PC,. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011; 47: 2202-2210.
27. Arias E,. United States life tables 2000. Natl Vital Stat Rep. 2002; 21: 1-39.
28. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997; 89: 3323-3329.
29. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006; 108: 63-73.
30. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006; 108: 3280-3288.
31. Pulte D, Gondos A, Brenner H,. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008; 93: 594-600.
32. Whitman SP, Maharry K, Radmacher MD, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood. 2010; 116: 3622-3626.
33. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361: 1235-1248.
34. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010; 116: 4422-4429.
35. Oran B, Weisdorf DJ,. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012; 97: 1916-1924.
36. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM,. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012; 119: 34-43.
37. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T,. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004; 18: 120-125.
38. Kayser S, Dohner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011; 117: 2137-2145.